Thalidomide increases human keratinocyte migration and proliferation

Journal of Investigative Dermatology

Volumn 113, Issue 5, 1999, Pages 720-724

  Nasca, Maria R ^a   O'Toole, Edel A ^b   Palicharla, Prema ^b   West, Dennis P ^b   Woodley, David T ^b,c  

^a UNIVERSITY OF CATANIA   (Italy)

^b NORTHWESTERN UNIVERSITY   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Cytokine; Re epithelialization; Wound healing

Indexed keywords

CHEMOKINE; COLLAGEN TYPE 1; COLLOIDAL GOLD; INTERLEUKIN 8; METALLOPROTEINASE; THALIDOMIDE;

APHTHOUS ULCER; ARTICLE; AUTOCRINE EFFECT; BEHCET DISEASE; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CHEMOTAXIS; CONTROLLED STUDY; DRUG EFFECT; EPITHELIZATION; HUMAN; HUMAN CELL; KERATINOCYTE; PRIORITY JOURNAL; PYODERMA GANGRENOSUM; SKIN INJURY;

EID: 0032735236     PISSN: 0022202X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1747.1999.00744.x     Document Type: Article

References (52)

1. Albrecht-Buehler G: The phagokinetic tracks of 3T3 cells. Cell 11:395-404, 1977
2. Barnhill RL, Doll NJ, Millikan LE, Hastings RC: Studies on the anti-inflammatory properties of thalidomide: effects on polymorphonuclear leukocytes and monocytes. J Am Acad Dermatol 11:815-819, 1984
3. Boughton BJ, Sheehan TM, Wood J, O'Brien D, Butler M, Simpson A, Hale KA: High-performance liquid chromatographic assay of plasma thalidomide: Stabilization of specimens and determination of a tentative therapeutic range for chronic graft-versus-host disease. Ann Clin Biochem 32:79-83, 1995
4. Boyce ST, Ham RG: Calcium-regulated differentiation of normal human epidermal keratinocytes in chemically defined clonal culture and serum-free serial culture. J Invest Dermatol 81:33s-40s, 1983
5. Cha D, O'Brien P, O'Toole EA, Woodley DT, Hudson LG: Enhanced modulation of keratinocyte motility by transforming growth factor-α (TGF-α) relative to epidermal growth factor (EGF). J Invest Dermatol 106:590-597, 1996
6. 2 integrin subunit. Exp Cell Res 209:216-223, 1993
7. Chen TL, Vogelsang GB, Petty BG, Brudrett RB, Noc DA, Santos GW, Colvin OM: Plasma pharmacokinetics and urinary excretion of thalidomide after oral dosing in healthy male volunteers. Drug Metabol Dispos 17:402-405, 1989
8. Costa I, Castanet J, Taillan B, et al: Adénites aseptiques au cours d'un pyoderma gangrenosum. Ann Dermatol Venereol 121:550-552, 1994
9. D'Amato RJ, Loughnan MS, Flynn E, Folkman J: Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 9:4081-4085, 1994
10. Gad SM, Shannon EJ, Krotoski WA, Hasting RC: Thalidomide induces imbalances in T-lymphocyte subpopulations in the circulating blood of healthy males. Lepr Rev 56:35-39, 1985
11. Gardner-Medwin JM, Powell RJ: Thalidomide - the way forward. Postgrad Med J 70:860-862, 1994a
12. Gardner-Medwin JMM, Smith NJ, Powell RJ: Clinical experience with thalidomide in the management of severe oral and genital ulceration in conditions as Behçet's disease: use of neurophysiological studies to detect thalidomide neuropathy. Ann Rheum Dis 53:828-832, 1994b
13. Grinspan D, Fernandez Blánco G, Agüero S: Treatment of aphthae with thalidomide. J Am Acad Dermatol 20:1060-1063, 1989
14. Grosshans E, Illy G: Thalidomide therapy for inflammatory dermatoses. Int J Dermatol 23:598-602, 1984
15. Hecker MS, Lebwohl MG: Recalcitrant pyoderma gangrenosum: treatment with thalidomide. J Am Acad Dermatol 38:490-49, 1998
16. Iwasaki T, Chen JD, Kim JP, Wynn KC, Woodley DT: Dibutryl cyclic AMP modulates keratinocyte migration without alteration of integrin expression. J Invest Dermatol 102:891-897, 1994
17. Jacobson J, Greenspan JS, Spritzler J, et al: Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. N Engl J Med 336:1487-1493, 1997
18. McHugh SM, Rifkin IR, Deighton J, Wilson AB, Lachmann PJ, Lockwood CM, Ewan PW: The immunosuppressive drug thalidomide induces T-helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures. Clin Exp Immunol 99:160-167, 1995
19. Moncada B, Baranda ML, Gonzalez-Amaro R, Urbina R, Loredo CE: Thalidomide effect on T cell subsets as a possible mechanism of action. Int J Lepr 53:201-205, 1985
20. Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G: Thalidomide exerts its inhibitory action on tumor necrosis factor a by enhancing mRNA degradation. J Exp Med 177:1675-1680, 1993
21. Munro CS, Cox NH: Pyoderma gangrenosum associated with Behçet's syndrome-response to thalidomide. Clin Exp Dermatol 13:408-410, 1988
22. Naafs B, Faber WR: Thalidomide therapy. An open trial. Int J Dermatol 24:131-134, 1985
23. Nasca MR, Micali G, West DP: Thalidomide - a review, in press, 1999
24. Neubert R, Nogueira AC, Neubert D: Thalidomide and the immune system. 2. Changes in receptors on blood cells of a healthy volunteer. Life Sci 51:2107-2116, 1992
25. Neubert R, Nogueira AC, Neubert D: Thalidomide derivatives and the immune system. I. Changes in the pattern of integrin receptors and other surface markers on T lymphocyte subpopulations of marmoset blood. Arch Toxicol 67:1-17, 1993
26. Neubert R, Hinz N, Thiel R, Neubert D: Down-regulation of adhesion receptors on cells of primate embryos as a probable mechanism of the teratogenic action of thalidomide. Life Sci 58:295-316, 1996
27. Nickoloff BJ, Karabin GD, Barker JN, et al: Cellular localization of interleukin-8 and its inducer, tumor necrosis factor-alpha in psoriasis. Am J Pathol 138:129-140, 1991
28. Nickoloff BJ, Mitra RS, Varani J, Dixit VM, Polverini PJ: Aberrant production of interleukin-8 and thrombospondin 1 by psoriatic keratinocytes mediates angiogenesis. Am J Pathol 144:820-828, 1994
29. Nogueira AC, Neubert R, Helge H, Neubert D: Thalidomide and the immune system. 3. Simultaneous up- and down-regulation of different integrin receptors on human white blood cells. Life Sci 55:77-92, 1994
30. O'Keefe EJ, Chiu ML: Stimulation of thymidine incorporation in keratinocytes by insulin, epidermal growth factor, and placental extract: comparison with cell number to assess growth. J Invest Dermatol 90:2-7, 1988
31. O'Toole EA, Marinkovich MP, Peavey CL, Amieva MR, Furthmayr H, Mustor TA, Woodley DT: Hypoxia increases human keratinocyte motility on connective tissue. J Clin Invest 100:2881-2891, 1997
32. Ochonisky S, Revuz J: Thalidomide use in dermatology. Eur J Dermatol 4:9-15, 1994
33. Odland G, Ross R: Human wound repair. I. Epidermal regeneration. J Cell Biol 39:135-151, 1968
34. Paterson DL, Georghiou PR, Allworth AM, Kemp RJ: Thalidomide as treatment of refractory aphthous ulceration related to human immunodeficiency virus infection. Clin Infect Dis 20:250-254, 1995
35. Petersen MJ, Woodley DT, Stricklin GP, O'Keefe EJ: Production of procollagenase by cultured human keratinocytes. J Biol Chem 262:835-840, 1987
36. Petersen MJ, Woodley DT, Stricklin GP, O'Keefe EJ: Constitutive production of procollagenase and tissue inhibitor of metalloproteinases by human keratinocytes in culture. J Invest Dermatol 92:156-159, 1989
37. Racher AJ, Looby D, Griffiths JB: Use of lactate dehydrogenase release to assess changes in culture viability. Cytotechnology 3:301-307, 1990
38. Revuz J: Actualité du thalidomide. Ann Dermatol Venereol 117:313-321, 1990
39. Revuz J, Guillaume J-C, Janier M, et al: Crossover study of thalidomide vs placebo in severe recurrent aphthous stomatitis. Arch Dermatol 126:923-927, 1990
40. Rustin MHA, Gilkes JJH, Robinson TWE: Pyoderma gangrenosum associated with Behçet's disease: treatment with thalidomide. J Am Acad Dermatol 23:941-944, 1990
41. Sampaio EP, Samo EN, Galilly R, Cohn ZA, Kaplan G: Thalidomide selectively inhibits tumor necrosis factor α production by stimulated human monocytes. J Exp Med 173:699-703, 1991
42. Sarret Y, Woodley DT, Goldberg GS, Kronberger A, Wynn KC: Constitutive synthesis of a 92-kDa keratinocyte-derived type IV collagenase is enhanced by type 1 collagen and decreased by type IV collagen matrices. J Invest Dermatol 99:836-841, 1992a
43. Sarret Y, Woodley DT, Grigsby K, Wynn K, O'Keefe EJ: Human keratinocyte locomotion: the effect of selected cytokines. J Invest Dermatol 98:400-405, 1992b
44. Schröder JM: Chemotactic cytokines in the epidermis. Exp Dermatol 1:12-19, 1992
45. Shannon EJ, Ejigu M, Haile-Mariam HS, Berhan TY, Tasesse G: Thalidomide's effectiveness in erythema nodosum leprosum is associated with a decrease in CD4+ cells in the peripheral blood. Lepr Rev 63:5-11, 1992
46. Sheskin J: Thalidomide in the treatment of lepra reaction. Clin Pharmacol Ther 6:303-306, 1965
47. Sheskin J: The treatment of lepra reaction in lepromatous leprosy: fifteen years' experience with thalidomide. Int J Dermatol 19;318-322, 1980
48. Tannesh MG, Worther GS, Johnston RBJ. Neutrophil emigration activation and tissue damage. In: Clark RAF, Hanson PM (eds). Molecular and Cellular Biology of Wound Repair. New York: Plenum Press, 1988
49. Tseng S, Pak G, Washenik K, Keltz Pomeranz M, Shupack JL: Rediscovering thalidomide: a review of its mechanism of action, side effects and potential uses. J Am Acad Dermatol 35:969-979, 1996
50. Tuschil A, Lam C, Haslberger A, Lindley I: Interleukin-8 stimulates calcium transients and promotes epidermal cell proliferation. J Invest Dermatol 99:294-298, 1992
51. Woodley DT, Bachmann PM, O'Keefe EJ: Laminin inhibits human keratinocyte migration. J Cell Physiol 136:140-146, 1988
52. Woodley DT, Chen JD, Kim JP, Sarret Y, Iwasaki T, Kim YH, O'Keefe EJ: Re-epithelialization. Human keratinocyte locomotion. Dermatol Clin 11:641-646, 1993